At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
ORM-12741 +2 moredrug
Likely dose
ORM-12741 60mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of ORM-12741 on Cognitive and Behavioral Symptoms in Patients With Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating ORM-12741 and Placebo for ORM-12741 for Alzheimer's Disease. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesFinland
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartApr 2011
Primary CompletionSep 2012
Study CompletionOct 2012
TodayJul 2026
First PostedMar 29, 2011
Enrollment StartApr 1, 2011
Primary CompletionSep 1, 2012
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.3 years ago
Interventions
ORM-12741drug
60mg twice a day
ORM-12741drug
200mg twice a day
Placebo for ORM-12741drug
Placebo twice a day